Compare TOUR & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | RPTX |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 92.4M |
| IPO Year | 2014 | 2020 |
| Metric | TOUR | RPTX |
|---|---|---|
| Price | $0.68 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 154.0K | ★ 1.5M |
| Earning Date | 12-05-2025 | 03-02-2026 |
| Dividend Yield | ★ 5.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $78,261,883.00 | $11,870,000.00 |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $10.18 | $3,233.33 |
| P/E Ratio | $102.53 | ★ N/A |
| Revenue Growth | ★ 9.07 | N/A |
| 52 Week Low | $0.62 | $0.89 |
| 52 Week High | $1.17 | $2.66 |
| Indicator | TOUR | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 65.65 |
| Support Level | $0.62 | $2.52 |
| Resistance Level | $0.72 | $2.61 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 46.64 | 29.63 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.